[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kala Bio Inc (KALA)

Kala Bio Inc (KALA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 104,196
  • Shares Outstanding, K 929,492
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,980 K
  • EBIT $ -39 M
  • EBITDA $ -40 M
  • 60-Month Beta -2.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.15
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.33
  • Most Recent Earnings $0.86 on 04/15/26
  • Next Earnings Date 05/13/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0996 +15.56%
on 05/06/26
0.2370 -51.43%
on 04/13/26
-0.0578 (-33.43%)
since 04/06/26
3-Month
0.0996 +15.56%
on 05/06/26
0.5100 -77.43%
on 03/11/26
-0.3249 (-73.84%)
since 02/06/26
52-Week
0.0996 +15.56%
on 05/06/26
20.6000 -99.44%
on 09/17/25
-3.3349 (-96.66%)
since 05/06/25

Most Recent Stories

More News
Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments

SUMMIT, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER ) (“Aterian” or the “Company” ), a consumer products company, today announced separate transactions related to...

FIEE : 6.33 (-7.99%)
BGMS : 1.0000 (-2.91%)
YHC : 0.9000 (-0.37%)
KALA : 0.1151 (+2.68%)
OPGN : 24.7500 (+3.13%)
ATER : 1.2600 (unch)
BTTC : 1.3500 (+10.66%)
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“ KALA ” or the “ Company ”) today celebrated the landmark Executive Order signed by U.S. President Donald...

TRUFF : 0.0297 (-10.54%)
TRIP.CN : 0.0450 (unch)
KALA : 0.1151 (+2.68%)
KALA BIO: Q4 Earnings Snapshot

KALA BIO: Q4 Earnings Snapshot

KALA : 0.1151 (+2.68%)
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company at the forefront of artificial intelligence and cell and gene therapy innovation,...

KALA : 0.1151 (+2.68%)
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

ARLINGTON, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“Kala” or the “Company”) today announced the initial commercial deployment of the Bionic Intelligence Research...

KALA : 0.1151 (+2.68%)
Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate

AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry TORONTO...

TRUFF : 0.0297 (-10.54%)
TRIP.CN : 0.0450 (unch)
KALA : 0.1151 (+2.68%)
Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents

Open-source breakthrough demonstrates AI agents can run 100+ experiments overnight-reinforcing the agentic R&D paradigm Researgency.ai is bringing to life sciences with Kala Bio (KALA)Toronto, Ontario--(Newsfile...

KALA : 0.1151 (+2.68%)
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

ARLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) announces that it is ready to ship its first commercial AI product in approximately 14 days, transforming the Company...

KALA : 0.1151 (+2.68%)
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform...

Company launches initiative to become a dedicated AI infrastructure partner for the biotechnology industry — to deploy secure, on-premises AI systems directly within client environments where proprietary...

KALA : 0.1151 (+2.68%)
KALA BIO Settles Approximately $10.6 million of Debt

ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), (“KALA” or the “Company”) today announced the successful completion of its loan settlement with Oxford Finance,...

KALA : 0.1151 (+2.68%)

Business Summary

KALA BIO is a clinical-stage biopharmaceutical company. It focused on the research, development and commercialization of therapies for rare and severe diseases of the eye. The company' s lead product candidate consists KPI-012. KALA BIO, formerly known as Kala Pharmaceuticals Inc., is based in ARLINGTON,...

See More

Key Turning Points

3rd Resistance Point 0.1389
2nd Resistance Point 0.1280
1st Resistance Point 0.1215
Last Price 0.1151
1st Support Level 0.1041
2nd Support Level 0.0932
3rd Support Level 0.0867

See More

52-Week High 20.6000
Fibonacci 61.8% 12.7688
Fibonacci 50% 10.3498
Fibonacci 38.2% 7.9308
Last Price 0.1151
52-Week Low 0.0996

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.